3i has agreed to sell Xellia Pharmaceuticals AS, a Norwegian speciality pharmaceutical group, to Novo AS for £460m.
PME invests via Fundo 200M, a €200m co-investment vehicle that supports the expansion of Portuguese startups
Series-B round follows a seed round in 2018, backed by BtoV, AM Ventures and Unternehmertum
Andera Partners and Boehringer Ingelheim Venture Fund also backed the T-cell therapy developer
Glass Container companies are portfolio companies of Horizon Capital’s Western NIS Enterprise Fund